Mark A. Carfagna
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Immunotoxicology and immune responses, Antimicrobial Resistance in Staphylococcus, Pharmacogenetics and Drug Metabolism, Gene expression and cancer classification
Most-Cited Works
- → Temporal Gene Expression Analysis of Monolayer Cultured Rat Hepatocytes(2001)146 cited
- → Kinetic Analysis of Furan Biotransformation by F-344 Rats in Vivo and in Vitro(1993)128 cited
- → Inhibition of ATPase activity in rat synaptic plasma membranes by simultaneous exposure to metals(1996)75 cited
- → Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes(2005)70 cited
- → Comparison of Plasma, Serum, and Whole Blood Ethanol Concentrations(1987)69 cited
- → Furan-Induced Cytolethality in Isolated Rat Hepatocytes: Correspondence with in Vivo Dosimetry(1993)64 cited
- → Furan-Mediated Uncoupling of Hepatic Oxidative Phosphorylation in Fischer-344 Rats: An Early Event in Cell Death(1997)57 cited
- → Involvement of calcium channels in the sexual dimorphism of cadmium-induced hepatotoxicity(2003)37 cited
- → Effects of Dialysis Membrane on Intradialytic Vancomycin Administration(1997)32 cited
- → Falsely elevated serum vancomycin concentrations in hemodialysis patients(1996)31 cited